LPTX — Leap Therapeutics Share Price
0.000.00%
Last trade - 00:00- $75.00m
- $20.08m
- 26
- 21
- 30
- 15
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.55 | ||
| Price to Tang. Book | 1.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -124.44% | ||
| Return on Equity | -74.43% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.5 | 1.5 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Directors
- Christopher Mirabelli CHM (66)
- Douglas Onsi PRE (52)
- Augustine Lawlor COO (65)
- Christine Granfield VPR (53)
- Mark O'Mahony OTH (50)
- Cynthia Sirard OTH (51)
- Thomas Dietz LED (57)
- Monica Bertagnolli IND (62)
- James Cavanaugh IND (82)
- William Li IND (58)
- Joseph Loscalzo IND (69)
- Nissim Mashiach IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 3rd, 2011
- Public Since
- January 24th, 2017
- No. of Shareholders
- 74
- No. of Employees
- 54
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 38,264,464
- Address
- 47 Thorndike St Ste B1-1, CAMBRIDGE, 02141-1799
- Web
- https://www.leaptx.com/
- Phone
- +1 6172524343
- Auditors
- EisnerAmper LLP
Upcoming Events for LPTX
Q2 2024 Leap Therapeutics Inc Earnings Release
Q3 2024 Leap Therapeutics Inc Earnings Release
Similar to LPTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Leap Therapeutics share price?
As of Today at 21:47 UTC, shares in Leap Therapeutics are trading at $1.92. This share price information is delayed by 15 minutes.
How has the Leap Therapeutics share price performed this year?
Shares in Leap Therapeutics last closed at $1.92 and the price had moved by -54.29% over the past 365 days. In terms of relative price strength the Leap Therapeutics share price has underperformed the S&P500 Index by -63.62% over the past year.
What are the analyst and broker recommendations for Leap Therapeutics?
The overall consensus recommendation for Leap Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Leap Therapeutics dividend yield?
Leap Therapeutics does not currently pay a dividend.
Does Leap Therapeutics pay a dividend?
Leap Therapeutics does not currently pay a dividend.
When does Leap Therapeutics next pay dividends?
Leap Therapeutics does not currently pay a dividend.
How do I buy Leap Therapeutics shares?
To buy shares in Leap Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Leap Therapeutics?
As of the previous close price of $1.92, shares in Leap Therapeutics had a market capitalisation of $73.47m.
Where are Leap Therapeutics shares listed?
Here are the trading details for Leap Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LPTX
What kind of share is Leap Therapeutics?
Based on an overall assessment of its quality, value and momentum Leap Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Leap Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Leap Therapeutics is $11.38. That is 492.71% above the last closing price of $1.92.
Analysts covering Leap Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.71 for the next financial year.
What is the trend in the Leap Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Leap Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -48.22%.
As of the last closing price of $1.92, shares in Leap Therapeutics were trading -23.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Leap Therapeutics PE Ratio?
The Leap Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Leap Therapeutics?
Leap Therapeutics' management team is headed by:
- Christopher Mirabelli - CHM
- Douglas Onsi - PRE
- Augustine Lawlor - COO
- Christine Granfield - VPR
- Mark O'Mahony - OTH
- Cynthia Sirard - OTH
- Thomas Dietz - LED
- Monica Bertagnolli - IND
- James Cavanaugh - IND
- William Li - IND
- Joseph Loscalzo - IND
- Nissim Mashiach - IND